We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01454531
First Posted: October 19, 2011
Last Update Posted: March 6, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
ALK-Abelló A/S
October 13, 2011
October 19, 2011
December 3, 2014
March 6, 2015
March 6, 2015
June 2011
March 2012   (Final data collection date for primary outcome measure)
Frequency of Subjects With Adverse Drug Reactions [ Time Frame: 6 weeks ]
Frequency of patients with adverse reactions, local or systemic
To assess the tolerability of AVANZ [ Time Frame: 6 weeks ]
The frequency of patients with adverse reactions will be the study primary endpoint.
Complete list of historical versions of study NCT01454531 on ClinicalTrials.gov Archive Site
  • Frequency of Subjects With Systemic Reactions [ Time Frame: 6 weeks ]
    Frequency of patients with systemic reactions, based on EAACI classification: Grade I (mild systemic reaction) to IV (anaphylactic shock)
  • Frequency of Subjects With Local Adverse Reaction [ Time Frame: 6 weeks ]
    Frequency of patients with local adverse reactions
  • Change in Phleum Pratense Specific IgE-blocking Factor [ Time Frame: baseline (visit 1) and at 6 weeks (visit 6) ]

    IgE-blocking factor measures the amount of IgE bound to the allergen in the presence of allergen-competing factors present in the serum of a subject treated with allergen immunotherapy. The test is based in a double IgE measurement, an ordinary assay and an assay in the presence of competing components and takes the form of:

    IgE blocking factor = 1 - (Competitive IgE/Ordinary IgE). Theoretical limits are from 0 (no IgE blocked) to 1 (all IgE blocked) and, being a ratio, is a dimensionless measure

  • Change in Phleum Pratense Specific IgG4 [ Time Frame: baseline (visit 1) and at 6 weeks (visit 6) ]
  • Change in Immediate Cutaneous Response to Phleum Pratense [ Time Frame: baseline (visit 1) and at 6 weeks (visit 6) ]
    Wheal size provoked after prick test with 4, 20 and 100 µg/ml Phl p 5 allergen extracts analysed by Parallel Line Assay. Cutaneous Tolerance Index (CTI) is the factor it is necessary to multiply the extract concentration by after SCIT (V6) to obtain the same response in terms of wheal area as at baseline (V1). CTI, being an index, is a dimensionless measure. A CTI of 1 indicates no change in skin sensitivity while if higher than 1 a decrease in skin sensitivity (it would be needed a more concentrated allergen extract at V6 to elicit the same skin response as at V1
Frequency of systemic reactions and Change in immunological parameters [ Time Frame: 6 weeks ]
Frequency of systemic reactions, based on EAACI classification, increase in IgG4 and in IgE-blocking factor; reduction in immediate skin reactivity.
Not Provided
Not Provided
 
An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy
An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy
The purpose of this study is to assess the tolerability of AVANZ.
To assess the tolerability of the up-dosing phase of AVANZ Phleum pratense. The frequency of patients with adverse reactions will be the study primary endpoint.
Interventional
Phase 2
Phase 3
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Allergic Rhinoconjunctivitis
Drug: AVANZ Phleum pratense
AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
Experimental: AVANZ Phleum pratense
AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
Intervention: Drug: AVANZ Phleum pratense
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
199
April 2012
March 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • History of grass pollen rhinoconjunctivitis
  • Positive SPT to Phleum pratense
  • Positive specific IgE against Phleum pratense

Exclusion Criteria:

  • Uncontrolled severe asthma
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
 
NCT01454531
AV-G-01
No
Not Provided
Not Provided
ALK-Abelló A/S
ALK-Abelló A/S
Not Provided
Principal Investigator: JOAQUIN SASTRE, MD, PhD FUNDACIÓN JIMÉNEZ DIAZ
ALK-Abelló A/S
February 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP